References

Modulation of PPAR-α and PPAR-γ influences cardiomyocyte growth and cardiac remodeling

10.1002/iub.70035 · ExternalCitation · doi-reference

Cytotoxicity and toxicoproteomics analysis of thiazolidinedione exposure in human-derived cardiomyocytes

10.1002/jat.4613 · ExternalCitation · doi-reference

Antiapoptotic and anti-inflammatory effects of PPARγ agonist, pioglitazone, reversed doxorubicin-induced cardiotoxicity in rats

10.1002/jbt.23041 · ExternalCitation · doi-reference

Peroxisome proliferator-activated receptor gamma prevents activation of RBL-2H3 cells via suppressing NF-κB signaling

10.1007/s00011-025-02022-7 · ExternalCitation · doi-reference

Peroxisome proliferator activated receptor-gamma (PPAR-γ) ligand, pioglitazone, increases analgesic and anti-inflammatory effects in formalin-induced nociception

10.1007/s00210-023-02715-y · ExternalCitation · doi-reference

Gestationally administered RAS modulators reprogram endotoxic cardiovascular responses in adult rat offspring

10.1007/s00210-024-03305-2 · ExternalCitation · doi-reference

Effects of oral antidiabetic agents on the renin-angiotensin-aldosterone system: a systematic review

10.1007/s00228-025-03830-w · ExternalCitation · doi-reference

Hyperglycemia aggravates blood-brain barrier disruption following diffuse axonal injury and increases vascular permeability

10.1007/s10753-022-01716-y · ExternalCitation · doi-reference

Possible role of rice bran extract in microglial modulation through PPAR-gamma receptors in a rat model of neuroinflammation

10.1007/s11011-021-00741-4 · ExternalCitation · doi-reference

Toxicometabolomics-based cardiotoxicity evaluation of thiazolidinediones in human-derived cardiomyocytes

10.1007/s11306-024-02097-z · ExternalCitation · doi-reference

Integrative analysis of toxicometabolomics and toxicoproteomics data reveals multi-level cardiotoxicity mechanisms of thiazolidinediones

10.1007/s11306-024-02201-3 · ExternalCitation · doi-reference

The effects of antidiabetic agents on heart failure: a narrative review

10.1007/s12471-021-01579-2 · ExternalCitation · doi-reference

The impact of different antidiabetic drugs on fracture risk and cardiovascular outcomes: a network meta-analysis

10.1016/j.ajmo.2025.100115 · ExternalCitation · doi-reference

Metallothionein alleviates glutathione depletion-induced oxidative cardiomyopathy and contractile dysfunction in mice

10.1016/j.ajpath.2024.02.009 · ExternalCitation · doi-reference

PPARγ activation inhibits PDGF-induced pulmonary artery smooth muscle cell proliferation and migration through PTEN upregulation

10.1016/j.biopha.2022.113233 · ExternalCitation · doi-reference

Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: a real-world cohort study

10.1016/j.diabres.2023.110685 · ExternalCitation · doi-reference

Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention and cardiac hypertrophy in type 2 diabetic mice with NASH

10.1016/j.ejphar.2021.174076 · ExternalCitation · doi-reference

Dysregulated ACE/ang II/Ang1–7 signaling provokes cardiovascular and inflammatory sequelae in septic offspring

10.1016/j.ejphar.2022.175344 · ExternalCitation · doi-reference

Deoxyelephantopin—a novel PPARγ agonist regresses pressure overload-induced cardiac fibrosis and improves cardiac function

10.1016/j.ejphar.2023.175841 · ExternalCitation · doi-reference

SERCA2 dysfunction stimulates inflammation and causes pulmonary vascular remodeling: reversal by PPARγ activation

10.1016/j.ejphar.2025.178502 · ExternalCitation · doi-reference

Reassessing the risk-benefit profile of thiazolidinediones in the era of SGLT2 inhibitors and GLP-1 receptor agonists

10.1016/j.eprac.2025.04.004 · ExternalCitation · doi-reference

Activation of PPAR-γ prevents TERT-mediated pulmonary vascular remodeling in monocrotaline-induced pulmonary hypertension

10.1016/j.heliyon.2023.e14173 · ExternalCitation · doi-reference

Oxidized alkyl phospholipids stimulate sodium transport in proximal tubules through a non-genomic PPARγ-dependent pathway

10.1016/j.jbc.2022.101681 · ExternalCitation · doi-reference

Mitophagy disorder mediates cardiac deterioration induced by severe hypoglycemia in diabetic mice

10.1016/j.mce.2023.111994 · ExternalCitation · doi-reference

Canagliflozin improves fatty acid oxidation and ferroptosis in diabetic cardiomyopathy: implications for PPARγ cross-talk

10.1016/j.mce.2023.112139 · ExternalCitation · doi-reference

Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in oxidative phosphorylation in insulin-resistant humans

10.1016/j.metabol.2020.154416 · ExternalCitation · doi-reference

Insulin resistance and insulin sensitizing agents: from pathophysiology to clinical practice

10.1016/j.metabol.2021.154892 · ExternalCitation · doi-reference

Activation of PGC-1α and mitochondrial biogenesis by pioglitazone protects against prenatal hypoxic-ischemic brain injury

10.1016/j.neuroscience.2020.02.035 · ExternalCitation · doi-reference

Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

10.1016/j.numecd.2021.12.006 · ExternalCitation · doi-reference

Ginsenoside rd promotes cardiac regeneration through PPARG/HMGCS2-driven ketone body metabolic reprogramming

10.1016/j.phymed.2025.157694 · ExternalCitation · doi-reference

Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map

10.1016/s2213-8587(19)30422-x · ExternalCitation · doi-reference

Pioglitazone increases blood-brain barrier expression of fatty acid-binding protein 5 and plasma volume expansion markers

10.1021/acs.molpharmaceut.9b01131 · ExternalCitation · doi-reference

Assessing the need for pioglitazone in the treatment of type 2 diabetes in the context of cardiovascular outcome trials: a meta-analysis

10.1038/s41598-020-72967-8 · ExternalCitation · doi-reference

Pharmacologic and endotoxic reprogramming of renal vasodilatory signaling: role of PPARγ

10.1038/s41598-025-87586-4 · ExternalCitation · doi-reference

Pioglitazone-enhanced brown fat whitening contributes to weight gain and is associated with mitochondrial dysfunction

10.1055/a-2178-9113 · ExternalCitation · doi-reference

Pioglitazone after ischemic stroke or transient ischemic attack

10.1056/nejmoa1506930 · ExternalCitation · doi-reference

An in-depth review of PPARγ modulators as anti-diabetes therapeutics: from full agonists to selective modulators

10.1080/03602532.2025.2508152 · ExternalCitation · doi-reference

Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes: a focus on pioglitazone

10.1080/14656566.2022.2143263 · ExternalCitation · doi-reference

Treatment of type 2 diabetes patients with heart conditions: a practical approach

10.1080/17446651.2023.2204941 · ExternalCitation · doi-reference

Procyanidin B2 attenuates pathologic cardiac fibrosis and inflammation: role of PPARγ

10.1097/fjc.0000000000001684 · ExternalCitation · doi-reference

Pioglitazone ameliorates mitochondrial oxidative stress and inflammation in myocardial ischemia-reperfusion injury

10.1111/cpr.70109 · ExternalCitation · doi-reference

Efficacy of lower doses of pioglitazone after stroke: a post-hoc analysis of the IRIS trial

10.1111/dom.14687 · ExternalCitation · doi-reference

In praise of pioglitazone: a multifaceted insulin sensitiser

10.1111/dom.15222 · ExternalCitation · doi-reference

Cardiovascular efficacy and safety of antidiabetic agents: a focus on heart failure

10.1111/dom.15251 · ExternalCitation · doi-reference

Effect of combination pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists on cardiovascular outcomes in type 2 diabetes: a systematic review and meta-analysis

10.1111/dom.15576 · ExternalCitation · doi-reference

Sodium-glucose cotransporter 2 inhibitor ameliorates thiazolidinedione-induced fluid retention by protecting white adipose tissue vascular integrity

10.1111/dom.70356 · ExternalCitation · doi-reference

Worsening baroreflex sensitivity on progression to type 2 diabetes and its modulation by pioglitazone

10.1152/ajpendo.00145.2020 · ExternalCitation · doi-reference

Neuroprotective and anti-inflammatory effects of pioglitazone on traumatic brain injury: a review

10.1155/2022/9860855 · ExternalCitation · doi-reference

Pleural effusion and anasarca associated with pioglitazone: a case report

10.1177/87551225251348838 · ExternalCitation · doi-reference

Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug

10.1186/s12933-021-01294-7 · ExternalCitation · doi-reference

Prevalence and incidence of heart failure in type 2 diabetes patients: sex-specific differences

10.1186/s12933-024-02358-0 · ExternalCitation · doi-reference

Post mortem evaluation of inflammation, oxidative stress, and PPARγ activation in a nonhuman primate model of cardiac sympathetic neurodegeneration

10.1371/journal.pone.0226999 · ExternalCitation · doi-reference

PPARG agonist pioglitazone influences diurnal kidney medulla mRNA expression of core clock genes and ENaC subunits in mice

10.14814/phy2.15535 · ExternalCitation · doi-reference

Oral administration of pioglitazone inhibits pulmonary hypertension progression by modulating gut microbiome

10.14814/phy2.70174 · ExternalCitation · doi-reference

Pioglitazone protects against hypoxia-induced cardiomyocyte apoptosis by blocking the NLRP3/caspase-1 signaling pathway

10.1536/ihj.21-404 · ExternalCitation · doi-reference

Effect of SGLT2 inhibitors on thiazolidinedione-induced changes in volume status in patients with type 2 diabetes

10.20945/2359-4292-2024-0485 · ExternalCitation · doi-reference

Protective effects of pioglitazone on cognitive impairment and neuroinflammation in a rat model of Alzheimer’s disease

10.2147/dddt.s367229 · ExternalCitation · doi-reference

Pioglitazone alleviates β1-adrenergic receptor antibody-induced atrial fibrillation susceptibility by improving energy metabolism

10.2174/0109298673308673240527092317 · ExternalCitation · doi-reference

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis: role of PPARγ agonists

10.3350/cmh.2022.0237 · ExternalCitation · doi-reference

Clinical and pathophysiological links between hypoglycemia and cardiovascular risk in patients with diabetes

10.3389/fcdhc.2026.1765597 · ExternalCitation · doi-reference

Pioglitazone ameliorates gentamicin ototoxicity by preserving mitochondrial function

10.3389/fncel.2020.566148 · ExternalCitation · doi-reference

Pioglitazone inhibits diabetes-induced atrial mitochondrial oxidative stress and improves mitochondrial dynamics

10.3389/fphar.2021.658362 · ExternalCitation · doi-reference

Tribbles homolog 3-mediated vascular insulin resistance contributes to hypoxic pulmonary hypertension and is reversed by pioglitazone

10.3389/fphys.2020.542146 · ExternalCitation · doi-reference

PPARγ-independent side effects of thiazolidinediones on mitochondrial redox state in isolated rat hearts

10.3390/cells9010252 · ExternalCitation · doi-reference

Effects of hypoglycemia on cardiovascular function in patients with diabetes

10.3390/ijms24119357 · ExternalCitation · doi-reference

The impact of metformin on BNP levels in patients with type 2 diabetes

10.3390/jcm14082733 · ExternalCitation · doi-reference

Anti-diabetic therapy and heart failure: recent advances and mechanistic insights

10.3390/life13041024 · ExternalCitation · doi-reference

Review of the case reports on metformin, sulfonylurea, and thiazolidinedione therapies: focus on adverse events

10.3390/medsci11030050 · ExternalCitation · doi-reference

Unveiling an uncommon complication: pleural effusion secondary to pioglitazone use

10.55729/2000-9666.1541 · ExternalCitation · doi-reference

Small molecule inhibitor of PPARγ acetylation promotes insulin sensitization and browning of white adipose tissue with improved safety

10.64898/2025.12.15.694265 · ExternalCitation · doi-reference

Metabolic dysfunction-associated steatotic liver disease complicated by diabetes: pPARγ as a therapeutic target

10.7570/jomes25017 · ExternalCitation · doi-reference

Association of pioglitazone with major adverse cardiovascular events and heart failure: a systematic review and meta-analysis

10.7759/cureus.46911 · ExternalCitation · doi-reference

Etiology of drug-induced edema: a comprehensive review

10.7759/cureus.53400 · ExternalCitation · doi-reference

Screening for occult heart failure in type 2 diabetes mellitus using NT-proBNP: a retrospective cross-sectional study

10.7759/cureus.72576 · ExternalCitation · doi-reference